Latest Royalty Income News

Gullewa Limited reported significant progress in its South Darlot and British King projects, alongside a substantial royalty payment and a key board appointment in its latest quarterly update.

Talisman Mining’s recent drilling at Walkers Hill in NSW reveals promising shallow gold mineralisation, setting the stage for expanded exploration in the coming months. The company also reports solid royalty income and a healthy cash position.

Oliver’s Real Food Limited reports a strong September quarter with a 192% EBIT improvement and a positive operating cash flow turnaround, driven by cost efficiencies and strategic store closures.

Oliver’s Real Food Limited reported a striking turnaround in its September 2025 quarter, with EBIT soaring 192% and operating cash flow swinging positive despite a dip in overall revenue.

Juno Minerals has completed the sale of its Mount Mason DSO Hematite Project to Gold Valley Yilgarn for A$6 million cash plus a 2% royalty, with production set to start mid-2026. The deal strengthens Juno’s cash position while allowing focus on its flagship Mount Ida Magnetite Project.

Red Hill Minerals reports a profitable FY25 with robust royalty income from the Onslow Iron Project, declaring a fully franked final dividend of 6.5 cents per share.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

Weebit Nano Limited reported a strong FY25 with revenues surging over fourfold to $4.4 million and a narrowed net loss of $38.4 million, driven by key licensing deals and progress towards automotive-grade ReRAM qualification.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.